Should You Pick MRK Stock At $90?

1. Merck's Q4 revenue of $15.6B exceeded estimates, driven by Keytruda sales. 2. Adjusted earnings of $1.72 surpass consensus of $1.62; margins improved. 3. Guidance for 2025 fell short, weighing on stock performance post-announcement. 4. Gardasil sales dropped 17% due to lower demand in China; paused shipments. 5. MRK underperformed S&P 500 with -14% returns YTD; stock seen as volatile.